検索結果 47530 件
| フルテキストURL | K0005856_abstract_review.pdf K0005856_summary.pdf K0005856_fulltext.pdf |
|---|---|
| 著者 | 和田 望| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5856号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005855_abstract_review.pdf K0005855_summary.pdf K0005855_fulltext.pdf |
|---|---|
| 著者 | 酒谷 優佳| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5855号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005854_abstract_review.pdf K0005854_summary.pdf K0005854_fulltext.pdf |
|---|---|
| 著者 | 加藤 有加| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5854号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005853_abstract_review.pdf K0005853_summary.pdf K0005853_fulltext.pdf |
|---|---|
| 著者 | 益田 加奈| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5853号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005852_abstract_review.pdf K0005852_summary.pdf K0005852_fulltext.pdf |
|---|---|
| 著者 | 尾形 毅| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5852号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005851_abstract_review.pdf K0005851_summary.pdf K0005851_fulltext.pdf K0005851_fulltext_figure.pdf K0005851_fulltext_Supplementary_Figure.pdf |
|---|---|
| 著者 | 横道 直佑| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5851号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005850_abstract_review.pdf K0005850_summary.pdf K0005850_fulltext1.pdf |
|---|---|
| 著者 | 藤井 洋輔| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5850号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| フルテキストURL | K0005849_abstract_review.pdf K0005849_Summary.pdf K0005849_fulltext.pdf |
|---|---|
| 著者 | 栗田 真佐子| |
| 発行日 | 2018-12-27 |
| 資料タイプ | 学位論文 |
| 学位授与番号 | 甲第5849号 |
| 学位授与年月日 | 2018-12-27 |
| 学位・専攻分野 | 博士（医学） |
| 授与大学 | 岡山大学 |
| 言語 | 英語 |
| JaLCDOI | 10.18926/AMO/56466 |
|---|---|
| フルテキストURL | 73_1_93.pdf |
| Amo Type | Errata |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 93 |
| 終了ページ | 93 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| JaLCDOI | 10.18926/AMO/56465 |
|---|---|
| フルテキストURL | 73_1_91.pdf |
| 抄録 | In the article by Takase K et al. entitled “High-dose Dexamethasone Therapy as the Initial Treatment for Idiopathic Thrombocytopenic Purpura: Protocol for a Multicenter, Open-label, Single Arm Trial”, which appeared in the December 2018 issue, Vol.72, No.2, pp197-201, regarding the authors’ information in the first page, following corrections should be added as below. |
| Amo Type | Errata |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 91 |
| 終了ページ | 91 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| JaLCDOI | 10.18926/AMO/56464 |
|---|---|
| フルテキストURL | 73_1_85.pdf |
| 著者 | Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Nakano, Soichiro| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto| |
| 抄録 | Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. |
| キーワード | pneumocystis pneumonia prophylaxis systemic rheumatic disease sulfamethoxazole-trimethoprim conventional-dose versus half-dose |
| Amo Type | Clinical Study Protocol |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 85 |
| 終了ページ | 89 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820060 |
| JaLCDOI | 10.18926/AMO/56463 |
|---|---|
| フルテキストURL | 73_1_81.pdf |
| 著者 | Sugihara, Yuusaku| Harada, Keita| Oka, Shohei| Yasutomi, Eriko| Yamasaki, Yasushi| Inokuchi, Toshihiro| Kinugasa, Hideaki| Takahara, Masahiro| Hiraoka, Sakiko| Otsuka, Fumio| Okada, Hiroyuki| |
| 抄録 | Endoscopic submucosal dissection (ESD) is reportedly one of the standard treatment strategies for large superficial colorectal neoplasms in Japan because of its high en bloc resection rate. A few technical issues regarding ESD should be considered, one of which is the selection of the Endo-cut I mode versus the Swift-coagulation mode as the electrosurgical unit mode setting during submucosal dissection. We seek to determine which of these two modes is more suitable for submucosal dissections of colorectal tumors with regard to procedure time and safety. |
| キーワード | endoscopic submucosal dissection electrosurgical mode colorectal tumor |
| Amo Type | Clinical Study Protocol |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 81 |
| 終了ページ | 84 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820059 |
| JaLCDOI | 10.18926/AMO/56462 |
|---|---|
| フルテキストURL | 73_1_77.pdf |
| 著者 | Morita, Mio| Matsumoto, Hiroshi| Shirakawa, Yasuhiro| Noma, Kazuhiro| Tanabe, Shunsuke| Kimata, Yoshihiro| |
| 抄録 | Anterior cervical plate fixation is a common surgical treatment for cervical spine trauma, disc herniation, or cervical spondylosis. Esophageal perforation following anterior cervical plate fixation is a rare but serious complication. Management of esophageal perforation is controversial; however, we suggest treating most cases surgically because this condition is slow to heal and often fatal. We managed 2 cases of esophageal perforation following anterior cervical plate fixation by flap reconstruction with the pectoralis major muscle in one case and a jejunal free flap in the other. Here, we report our experience and review the surgical indications. |
| キーワード | anterior cervical plate fixation esophageal perforation reconstruction pectoralis major flap jejunal free flap |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 77 |
| 終了ページ | 80 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820058 |
| JaLCDOI | 10.18926/AMO/56461 |
|---|---|
| フルテキストURL | 73_1_71.pdf |
| 著者 | Takahashi-Arimasa, Keiko| Kohno-Yamanaka, Reiko| Soga, Yoshihiko| Miura, Rumi| Morita, Manabu| |
| 抄録 | Preoperative oral care is helpful to prevent postoperative complications in patients who are undergoing esophagectomy. Here, we report the case of an 81-year-old Japanese man with an upper limb disability caused by post-polio syndrome who was receiving neoadjuvant chemotherapy for esophageal cancer. He had poor oral health status and developed oral complications as a side effect of chemotherapy. He could not brush his teeth by himself. However, infection control by oral care provided by an interprofessional collaboration successfully improved his oral hygiene, and his follow-up involved no severe complications. Interprofessional collaboration is useful especially for patients with upper limb disability. |
| キーワード | esophageal cancer preoperative oral care post-polio syndrome neoadjuvant chemotherapy oral mucositis |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 71 |
| 終了ページ | 76 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820057 |
| JaLCDOI | 10.18926/AMO/56460 |
|---|---|
| フルテキストURL | 73_1_67.pdf |
| 著者 | Kono, Reika| Shimizu, Takehiro| Ohtsuki, Hiroshi| Hamasaki, Ichiro| Shibata, Kiyo| Kishimoto, Fumiko| Morizane, Yuki| Shiraga, Fumio| |
| 抄録 | We report a case of congenital multiple ocular motor nerve palsy combined with splitting of the lateral rectus muscle (LR). A 59-year-old Japanese female was investigated for worsening esotropia after corrective surgery. She presented with left hypertropia (35Δ) and esotropia (45-50Δ). Orbital magnetic resonance imaging (MRI) showed reduced belly sizes in the superior rectus, inferior rectus, and superior oblique muscles and splitting of the LR, extending from the origin to the belly, in the left eye. Splitting of the LR belly was detected on MRI in a case of congenital multiple ocular motor nerve palsy. |
| キーワード | multiple ocular motor nerve palsy congenital cranial dysinnervation disorder lateral rectus muscle splitting orbital connective tissue magnetic resonance imaging |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 67 |
| 終了ページ | 70 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820056 |
| JaLCDOI | 10.18926/AMO/56459 |
|---|---|
| フルテキストURL | 73_1_61.pdf |
| 著者 | Tamefusa, Kosuke| Ishida, Hisashi| Washio, Kana| Ishida, Toshiaki| Morita, Hirosuke| Shimada, Akira| |
| 抄録 | Patients with multi-system (MS)-type langerhans cell histiocytosis (LCH) show poor outcomes, especially congenital MS LCH cases were shown in high mortality rate. We experienced a congenital case of MS LCH with high risk organs, who needed intensive respiratory support after birth. Even though intensive chemotherapy was discontinued, this patient’s lung LCH lesions gradually became reduced and his respiratory condition recovered; therefore, we restarted and completed maintenance chemotherapy. The patient maintained complete remission for more than 4 years after the end of chemotherapy. Our case suggests that congenital MS LCH even with severe organ involvement can be treated successfully with chemotherapy. |
| キーワード | Langerhans-cell histiocytosis congenital multisystem type |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 61 |
| 終了ページ | 65 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820055 |
| レファレンス | Morimoto A, Oh Y, Shioda Y, Kudo K and Imamura T: Recent advances in Langerhans cell histiocytosis. Pediatr Int (2014) 56: 451-461.| Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K and Ladisch S: Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood (2013) 121: 5006-5014.| Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, Yasui M, Koga Y, Kobayashi R, Ishii E, Fujimoto J, Horibe K, Bessho F, Tsunematsu Y and Imashuku S: Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol (2016) 104: 99-109.| Nakashima T, Onoe Y, Tashiro A and Yamashita H: Congenital self-healing LCH: A case with lung lesions and review of the literature. Pediatr Int (2010) 52: 224-226.| Yu J De, Rubin AI, Castelo-Soccio L and Perman MJ: Congenital Self-Healing Langerhans Cell Histiocytosis. J Pediatr (2017) 184: 232-232.| Inoue M, Tomita Y, Egawa T, Ioroi T, Kugo M and Imashuku S: A Fatal Case of Congenital Langerhans Cell Histiocytosis with Disseminated Cutaneous Lesions in a Premature Neonate. Case Rep Pediatr (2016) 2016: 4972180.| Lucioni M, Beluffi G, Bandiera L, Zecca M, Inzani F, Fiandrino G, Viglio A, Stronati M, Necchi V, Riboni R, Locatelli F and Paulli M: Congenital aggressive variant of Langerhans cells histiocytosis with CD56+/E-Cadherin- phenotype. Pediatr Blood Cancer (2009) 53: 1107-1110.| Goñi-Orayen C, Ruiz-Cano R, Pérez-Martínez A, Escario-Travesedo E, Atienzar-Tobarra M and Martínez-Gutiérrez A: A fatal case of congenital disseminated Langerhans cell histiocytosis. J Perinat Med (1999) 27: 228-230.| Henter JI, Horne A, Aricò M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J and Janka G: HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 48: 124-131| Vassallo R, Harari S and Tazi A: Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax (2017) 72: 937-945.| Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne- Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert- Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias- Rodzewicz Z, Taly V, Geissmann F and Donadieu J: BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol (2016) 34: 3023-3030.| Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G and Nathwani BN: Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer (2013) 52: 99-106.| |
| JaLCDOI | 10.18926/AMO/56458 |
|---|---|
| フルテキストURL | 73_1_51.pdf |
| 著者 | Fujii, Masakuni| Fujimoto, Kenji| Yabe, Syuntaro| Nasu, Junichiro| Miyaike, Jiro| Yoshioka, Masao| Shiode, Junji| Yamamoto, Kazuhide| Matsuda, Shinya| |
| 抄録 | We investigated the relationship between body mass index (BMI) and postoperative outcomes in 450 gallbladder cancer patients in Japan. We collected patient information, including sex, age, underlying disease, BMI, stage, surgery method, postoperative time to discharge, and postoperative Medicare fees, from the Japanese administrative database associated with the Diagnosis Procedure Combination system. We classified patient BMIs as underweight (BMI<18.5 kg/m2), normal (BMI≥18.5 kg/m2 and <25 kg/m2) or overweight/obese (BMI≥25 kg/m2), then investigated the relationship between these categories and two postoperative outcomes: time to discharge and postoperative Medicare fees. The median postoperative time to discharge was 12 days in all patients, and 12 days in each of the three weight groups (p=0.62, n.s.). The median postoperative Medicare fees from surgery until discharge were (USD): all patients, $5,002; underweight, $5,875; normal weight, $4,797; and overweight/obese, $5,179 (p=0.146, n.s.). A multivariate analysis with adjustment for competing risk factors revealed that BMI was not associated with increased risk of longer postoperative time to discharge (normal weight: HR 1.17, p=0.29; overweight/obese: HR 1.17, p=0.37) or higher postoperative Medicare fees (OR 0.99, p=0.86, n.s.). Thus, high BMI was not found to be a factor for poor postoperative outcomes in Japanese patients with gallbladder cancer. |
| キーワード | body mass index gallbladder cancer surgery obesity |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 51 |
| 終了ページ | 59 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820054 |
| JaLCDOI | 10.18926/AMO/56457 |
|---|---|
| フルテキストURL | 73_1_43.pdf |
| 著者 | Ikeda, Ailee| Takaki, Akinobu| Yasunaka, Tetsuya| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Onishi, Hideki| Ikeda, Fusao| Shiraha, Hidenori| Yoshida, Kazuhiro| Kuise, Takashi| Nobuoka, Daisuke| Yoshida, Ryuichi| Umeda, Yuzo| Yagi, Takahito| Fujiwara, Toshiyoshi| Okada, Hiroyuki| |
| 抄録 | Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses. |
| キーワード | acute liver failure hepatitis B hepatitis B vaccine liver cirrhosis liver transplantation |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 41 |
| 終了ページ | 50 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820053 |
| レファレンス | Ishigami M, Ogura Y, Hirooka Y and Goto H: Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2015) 21: 10290-10298.| Kennedy M and Alexopoulos SP: Hepatitis B virus infection and liver transplantation. Curr Opin Organ Transplant (2010) 15: 310-315.| Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, Shinoura S, Umeda Y, Miyake Y, Terada R, Kobashi H, Sakaguchi K, Tanaka N and Shiratori Y: Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation (2007) 83: 231-233.| Takaki A, Yagi T and Yamamoto K: Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res (2015) 45: 38-47.| Holmberg SD, Suryaprasad A and Ward W: Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep (2012) 61: 1-12.| Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP and Manns MP: Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl (2007) 13: 367-373.| Yang A, Guo Z, Ren Q, Wu L, Ma Y, Hu A, Wang D, Ye H, Zhu X, Ju W and He X: Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study. PLoS One (2017) 12: e0188190.| Egawa H, Tanabe K, Fukushima N, Date H, Sugitani A and Haga H: Current status of organ transplantation in Japan. Am J Transplant (2012) 12: 523-530.| Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Yasuda Y, Nakayama E, Miyake Y, Ikeda F, Shiraha H, Nouso K, Fujiwara T and Yamamoto K: Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 48: 1373-1383.| Mochida S: Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res (2008) 38 Suppl 1: S52-55.| Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Nakanishi K, Yamashita K, Kamiyama T, Matsushita M and Todo S: Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Sci (2010) 17: 533-538.| Kasahara M, Sakamoto S, Horikawa R, Koji U, Mizuta K, Shinkai M, Takahito Y, Taguchi T, Inomata Y, Uemoto S, Tatsuo K and Kato S: Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry. Pediatr Transplant (2014) 18: 6-15.| Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M and Agarwal K: Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis (2018) 50: 944-953.| Schumann A, Lindemann M, Valentin-Gamazo C, Lu M, Elmaagacli A, Dahmen U, Knop D, Broelsch CE, Grosse-Wilde H, Roggendorf M and Fiedler M: Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation (2009) 87: 103-111.| Hu X, Ma S, Huang X, Jiang X, Zhu X, Gao H, Xu M, Sun J, Abbott WG and Hou J: Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat (2011) 18: 458-467.| Li Y, Tang L and Hou J: Role of interleukin-21 in HBV infection: friend or foe? Cell Mol Immunol (2015) 12: 303-308.| Soejima Y, Ikegami T, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yamashita Y and Maehara Y: Hepatitis B vaccination after living donor liver transplantation. Liver Int (2007) 27: 977–982.| Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK and Lee KU: Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology (2003) 37: 1329-1334.| Kwon CH, Suh KS, Yi NJ, Chang SH, Cho YB, Cho JY, Lee HJ, Seo JK and Lee KU: Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant (2006) 10: 479-486.| Lee S, Kim JM, Choi GS, Park JB, Kwon CH, Choe YH, Joh JW and Lee SK: De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers. Liver Transpl (2016) 22: 247-251.| Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, Yang CH, Yong CC, Lin TS, Jawan B, Cheng YF and Eng HL: Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant (2007) 7: 195-200.| Yoshizawa A, Yamashiki N, Ueda Y, Kaido T, Okajima H, Marusawa H, Chiba T and Uemoto S: Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res (2016) 46: 541-551.| Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Whittle H, Lambert PH, McAdam KP, Siegrist CA and Marchant A: Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine (2004) 22: 511-519.| Tuaillon E, Tabaa YA, Petitjean G, Huguet MF, Pajeaux G, Fondere JM, Ponseille B, Ducos J, Blanc P and Vendrell JP: Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBVimmunized subjects by ELISPOT assay. J Immunol Methods (2006) 315: 144-152.| Bauer T, Gunther M, Bienzle U, Neuhaus R and Jilg W: Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl (2007) 13: 434-442.| Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, Nashan B, Klempnauer J, Strassburg CP, Wedemeyer H and Manns MP: Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int (2006) 19: 828-833.| Di Paolo D, Lenci I, Cerocchi C, Tariciotti L, Monaco A, Brega A, Lotti L, Tisone G and Angelico M: One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int (2010) 23: 1105-1112.| Sintusek P, Posuwan N, Wanawongsawad P, Jitraruch S, Poovorawan Y and Chongsrisawat V: High prevalence of hepatitis B-antibody loss and a case report of de novo hepatitis B virus infection in a child after living-donor liver transplantation. World J Gastroenterol (2018) 24: 752-762.| |
| JaLCDOI | 10.18926/AMO/56456 |
|---|---|
| フルテキストURL | 73_1_29.pdf |
| 著者 | Matsumoto, Atsushi| Nakamura, Takehiro| Shinomiya, Aya| Kawakita, Kenya| Kawanishi, Masahiko| Miyake, Keisuke| Kuroda, Yasuhiro| Keep, Richard F.| Tamiya, Takashi| |
| 抄録 | Cerebral vasospasm (CVS) is a major contributor to the high morbidity and mortality of aneurysmal subarachnoid hemorrhage (aSAH) patients. We measured histidine-rich glycoprotein (HRG), a new biomarker of aSAH, in cerebrospinal fluid (CSF) to investigate whether HRG might be an early predictor of CVS. A total of seven controls and 14 aSAH patients (8 males, 6 females aged 53.4±15.4 years) were enrolled, and serial CSF and serum samples were taken. We allocated these samples to three phases (T1-T3) and measured HRG, interleukin (IL)-6, fibrinopeptide A (FpA), and 8-hydroxy-2’-deoxyguanosine (8OHdG) in the CSF, and the HRG in serum. We also examined the release of HRG in rat blood incubated in artificial CSF. In contrast to the other biomarkers examined, the change in the CSF HRG concentration was significantly different between the nonspasm and spasm groups (p<0.01). The rat blood/CSF model revealed a time course similar to that of the human CSF samples in the non-spasm group. HRG thus appears to have the potential to become an early predictor of CVS. In addition, the interaction of HRG with IL-6, FpA, and 8OHdG may form the pathology of CVS. |
| キーワード | biomarker histidine-rich glycoprotein predictor subarachnoid hemorrhage vasospasm |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 29 |
| 終了ページ | 39 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820052 |
| JaLCDOI | 10.18926/AMO/56455 |
|---|---|
| フルテキストURL | 73_1_21.pdf |
| 著者 | Oiwa, Yuko| Watanabe, Toyohiko| Sadahira, Takuya| Ishii, Ayano| Sako, Tomoko| Inoue, Miyabi| Wada, Koichiro| Kobayashi, Yasuyuki| Araki, Motoo| Nasu, Yasutomo| |
| 抄録 | We measured basal clitoral blood flow by Doppler sonography to determine whether tension-free vaginal mesh(TVM) affects the clitoral blood flow and sexual function in women with pelvic organ prolapse (POP). We performed a prospective study of 22 patients who underwent TVM for POP. Clitoral blood flow was measured by Doppler ultrasound. The resistance index (RI), pulsatility index (PI), peak systolic velocity (PSV), and end-diastolic velocity (EDV) of the clitoral arteries were measured preoperatively and at 1, 3, and 6 months postoperatively. Female sexual function was also investigated with the Female Sexual Function Index (FSFI). The mean PI and RI were increased at 1 month and significantly decreased at 6 months postoperatively (p<0.05). In contrast, the mean PSV and EDV decreased at 1 month postoperatively and increased at 6 months postoperatively. These four parameters recovered to baseline levels at 6 months following surgery. Total FSFI scores improved significantly from 10.2±7.9 at baseline to 18.2±8.9 at 6 months postoperatively. Color Doppler ultrasonography is potentially useful in measuring clitoral blood flow in patients treated with TVM for POP. Prospective long-term studies are needed to evaluate the utility of this modality as a diagnostic and prognostic tool for female sexual dysfunction. |
| キーワード | clitoris pelvic organ prolapse Doppler ultrasound |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-02 |
| 巻 | 73巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 21 |
| 終了ページ | 27 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 30820051 |